

82. The vector of claim 81, wherein said polynucleotide is operably associated with a regulatory sequence that regulates gene expression.

83. A host cell which comprises the isolated polynucleotide of claim 78.

84. A process for producing a host cell comprising transforming or transfecting a cell with the vector of claim 81.

85. A process for producing a polypeptide comprising culturing the host cell of claim 83 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.--

Remarks

Support for the claims can be found throughout the specification. The specification has been amended to insert priority information, to correct SEQ ID NO:s, and to insert a new sequence listing. The sequence listing differs in the addition of SEQ ID NO:125. SEQ ID NO:125 is identical to SEQ ID NO:1 of priority Appl. No. 08/845,496. Appl. No. 08/845,496 was incorporated by reference in its entirety in the captioned application. Thus, the addition of SEQ ID NO:125 in the substitute sequence listing does not constitute new matter. SEQ ID NO:125 from the original sequence listing is represented as SEQ ID NO:126 in the substitute sequence listing.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Andrea Jo Kamage

Andrea Jo Kamage
Agent for Applicants
Registration No. 43,703

Date: November 6, 2000

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600